Short answer
Dianthus Therapeutics, Inc. /DE/ (DNTH) filed its Q3 2025 10-Q quarterly report on Nov 5, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $396,000 with net income of −$37M.
Q3 2025 key financials · XBRL
- Revenue
- $396,000
- +105.2% QoQ
- Net income
- −$37M
- −46.0% YoY · −16.2% QoQ
- Operating margin
- -10173.7%
- EPS (diluted)
- −$0.97
- −31.1% YoY · −9.0% QoQ
Source: XBRL data from the Dianthus Therapeutics, Inc. /DE/ (DNTH) Q3 2025 10-Q on SEC EDGAR. USD.
Dianthus Therapeutics, Inc. /DE/ Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No new or updated risks disclosed this quarter compared to 10-K ended December 31, 2024
- Continued risk of material harm to business and stock price decline from events described in 10-K risks
- Operational risk from uncertainties inherent in drug development potentially impacting growth prospects
- Regulatory risk of reliance on FDA approvals and compliance affecting launch timing and market access
- Financial risk related to liquidity and capital requirements to fund ongoing clinical trials and operations
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Dianthus Therapeutics, Inc. /DE/ quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.